RU2627426C2 - Гемостатическое биологически абсорбируемое устройство с полиэтиленгликолем в качестве связующего вещества - Google Patents
Гемостатическое биологически абсорбируемое устройство с полиэтиленгликолем в качестве связующего вещества Download PDFInfo
- Publication number
- RU2627426C2 RU2627426C2 RU2014126807A RU2014126807A RU2627426C2 RU 2627426 C2 RU2627426 C2 RU 2627426C2 RU 2014126807 A RU2014126807 A RU 2014126807A RU 2014126807 A RU2014126807 A RU 2014126807A RU 2627426 C2 RU2627426 C2 RU 2627426C2
- Authority
- RU
- Russia
- Prior art keywords
- particles
- polyethylene glycol
- hemostatic
- fibrinogen
- hemostatic pad
- Prior art date
Links
- 230000002439 hemostatic effect Effects 0.000 title claims abstract description 118
- 239000002202 Polyethylene glycol Substances 0.000 title claims abstract description 37
- 229920001223 polyethylene glycol Polymers 0.000 title claims abstract description 37
- 239000000126 substance Substances 0.000 title abstract description 4
- 108010049003 Fibrinogen Proteins 0.000 claims abstract description 66
- 102000008946 Fibrinogen Human genes 0.000 claims abstract description 66
- 229940012952 fibrinogen Drugs 0.000 claims abstract description 66
- 108090000190 Thrombin Proteins 0.000 claims abstract description 62
- 229960004072 thrombin Drugs 0.000 claims abstract description 61
- 239000000463 material Substances 0.000 claims abstract description 58
- 239000000843 powder Substances 0.000 claims abstract description 47
- 239000002245 particle Substances 0.000 claims abstract description 46
- 238000000034 method Methods 0.000 claims abstract description 25
- 238000004519 manufacturing process Methods 0.000 claims abstract description 15
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 25
- 239000000835 fiber Substances 0.000 claims description 25
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 24
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 24
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 24
- 239000000725 suspension Substances 0.000 claims description 16
- 229920000642 polymer Polymers 0.000 claims description 14
- 239000012530 fluid Substances 0.000 claims description 10
- 238000002844 melting Methods 0.000 claims description 9
- 230000008018 melting Effects 0.000 claims description 9
- NOPJRYAFUXTDLX-UHFFFAOYSA-N 1,1,1,2,2,3,3-heptafluoro-3-methoxypropane Chemical compound COC(F)(F)C(F)(F)C(F)(F)F NOPJRYAFUXTDLX-UHFFFAOYSA-N 0.000 claims description 6
- 239000004627 regenerated cellulose Substances 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 4
- 238000001704 evaporation Methods 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 2
- 230000008020 evaporation Effects 0.000 claims description 2
- 238000005259 measurement Methods 0.000 claims 1
- 239000005445 natural material Substances 0.000 claims 1
- 238000005507 spraying Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 5
- 239000003814 drug Substances 0.000 abstract description 2
- 238000002360 preparation method Methods 0.000 description 45
- 238000012360 testing method Methods 0.000 description 38
- 210000001519 tissue Anatomy 0.000 description 30
- 206010052428 Wound Diseases 0.000 description 20
- 208000027418 Wounds and injury Diseases 0.000 description 20
- 239000000203 mixture Substances 0.000 description 19
- 239000011159 matrix material Substances 0.000 description 18
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 17
- 102000009123 Fibrin Human genes 0.000 description 15
- 108010073385 Fibrin Proteins 0.000 description 15
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 15
- 229920002560 Polyethylene Glycol 3000 Polymers 0.000 description 15
- 229950003499 fibrin Drugs 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 230000000740 bleeding effect Effects 0.000 description 11
- 239000000853 adhesive Substances 0.000 description 10
- 230000001070 adhesive effect Effects 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 239000004744 fabric Substances 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 239000007788 liquid Substances 0.000 description 8
- -1 polyglactin 910 Polymers 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 230000015271 coagulation Effects 0.000 description 7
- 238000005345 coagulation Methods 0.000 description 7
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 229920000249 biocompatible polymer Polymers 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- 239000004014 plasticizer Substances 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 229940030225 antihemorrhagics Drugs 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000002874 hemostatic agent Substances 0.000 description 5
- 229940106780 human fibrinogen Drugs 0.000 description 5
- 210000002381 plasma Anatomy 0.000 description 5
- 229920001282 polysaccharide Polymers 0.000 description 5
- 239000005017 polysaccharide Substances 0.000 description 5
- 150000004804 polysaccharides Chemical class 0.000 description 5
- 229960003766 thrombin (human) Drugs 0.000 description 5
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 4
- 239000012736 aqueous medium Substances 0.000 description 4
- 229960000074 biopharmaceutical Drugs 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 229920001577 copolymer Polymers 0.000 description 4
- 229920006037 cross link polymer Polymers 0.000 description 4
- 230000023597 hemostasis Effects 0.000 description 4
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 239000011241 protective layer Substances 0.000 description 4
- 108010088751 Albumins Proteins 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 3
- 101100111164 Arabidopsis thaliana BAC2 gene Proteins 0.000 description 3
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 3
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 3
- 239000004215 Carbon black (E152) Substances 0.000 description 3
- 229920001661 Chitosan Polymers 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 229920002201 Oxidized cellulose Polymers 0.000 description 3
- 239000003114 blood coagulation factor Substances 0.000 description 3
- 210000001772 blood platelet Anatomy 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 3
- 238000000280 densification Methods 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- 150000002430 hydrocarbons Chemical class 0.000 description 3
- 239000000017 hydrogel Substances 0.000 description 3
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 239000007791 liquid phase Substances 0.000 description 3
- 229940107304 oxidized cellulose Drugs 0.000 description 3
- 235000019271 petrolatum Nutrition 0.000 description 3
- 229920000728 polyester Polymers 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- 239000004264 Petrolatum Substances 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 239000000337 buffer salt Substances 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 229960002086 dextran Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229920013821 hydroxy alkyl cellulose Polymers 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 229940066842 petrolatum Drugs 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical compound CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 2
- 235000013772 propylene glycol Nutrition 0.000 description 2
- 235000004252 protein component Nutrition 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 239000013585 weight reducing agent Substances 0.000 description 2
- PJRSUKFWFKUDTH-JWDJOUOUSA-N (2s)-6-amino-2-[[2-[[(2s)-2-[[(2s,3s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[(2-aminoacetyl)amino]-4-methylsulfanylbutanoyl]amino]propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]propanoyl]amino]acetyl]amino]propanoyl Chemical compound CSCC[C@H](NC(=O)CN)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(N)=O PJRSUKFWFKUDTH-JWDJOUOUSA-N 0.000 description 1
- UJGHGRGFKZWGMS-UHFFFAOYSA-N 1,3-dioxan-2-one Chemical compound O=C1OCCCO1.O=C1OCCCO1 UJGHGRGFKZWGMS-UHFFFAOYSA-N 0.000 description 1
- KKGSHHDRPRINNY-UHFFFAOYSA-N 1,4-dioxan-2-one Chemical compound O=C1COCCO1.O=C1COCCO1 KKGSHHDRPRINNY-UHFFFAOYSA-N 0.000 description 1
- KXSKAZFMTGADIV-UHFFFAOYSA-N 2-[3-(2-hydroxyethoxy)propoxy]ethanol Chemical compound OCCOCCCOCCO KXSKAZFMTGADIV-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 229920000945 Amylopectin Polymers 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 108010027612 Batroxobin Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920002567 Chondroitin Polymers 0.000 description 1
- 102100023804 Coagulation factor VII Human genes 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 229920002558 Curdlan Polymers 0.000 description 1
- 239000001879 Curdlan Substances 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108010048049 Factor IXa Proteins 0.000 description 1
- 108010023321 Factor VII Proteins 0.000 description 1
- 108010054265 Factor VIIa Proteins 0.000 description 1
- 108010014173 Factor X Proteins 0.000 description 1
- 108010074864 Factor XI Proteins 0.000 description 1
- 108010080865 Factor XII Proteins 0.000 description 1
- 102000000429 Factor XII Human genes 0.000 description 1
- 108010071241 Factor XIIa Proteins 0.000 description 1
- 108010080805 Factor XIa Proteins 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 108010022901 Heparin Lyase Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000693243 Homo sapiens Paternally-expressed gene 3 protein Proteins 0.000 description 1
- 101000988229 Homo sapiens Protocadherin gamma-A12 Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 240000006240 Linum usitatissimum Species 0.000 description 1
- 235000004431 Linum usitatissimum Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102100025757 Paternally-expressed gene 3 protein Human genes 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 108010077971 Plasminogen Inactivators Proteins 0.000 description 1
- 102000010752 Plasminogen Inactivators Human genes 0.000 description 1
- 102000015795 Platelet Membrane Glycoproteins Human genes 0.000 description 1
- 108010010336 Platelet Membrane Glycoproteins Proteins 0.000 description 1
- HDSBZMRLPLPFLQ-UHFFFAOYSA-N Propylene glycol alginate Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(C)C(C(=O)OCC(C)O)O1 HDSBZMRLPLPFLQ-UHFFFAOYSA-N 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 102100029264 Protocadherin gamma-A12 Human genes 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 102000003800 Selectins Human genes 0.000 description 1
- 108090000184 Selectins Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- 208000031737 Tissue Adhesions Diseases 0.000 description 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229920013820 alkyl cellulose Polymers 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 229960002210 batroxobin Drugs 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 239000005388 borosilicate glass Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 238000009960 carding Methods 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 229940078035 curdlan Drugs 0.000 description 1
- 235000019316 curdlan Nutrition 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 108010085662 ecarin Proteins 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 229940012413 factor vii Drugs 0.000 description 1
- 229940012414 factor viia Drugs 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000010721 machine oil Substances 0.000 description 1
- 238000002074 melt spinning Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229960000292 pectin Drugs 0.000 description 1
- 108010021753 peptide-Gly-Leu-amide Proteins 0.000 description 1
- 239000002797 plasminogen activator inhibitor Substances 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 239000003805 procoagulant Substances 0.000 description 1
- AAEVYOVXGOFMJO-UHFFFAOYSA-N prometryn Chemical compound CSC1=NC(NC(C)C)=NC(NC(C)C)=N1 AAEVYOVXGOFMJO-UHFFFAOYSA-N 0.000 description 1
- 239000000770 propane-1,2-diol alginate Substances 0.000 description 1
- 235000010409 propane-1,2-diol alginate Nutrition 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000007151 ring opening polymerisation reaction Methods 0.000 description 1
- 239000003566 sealing material Substances 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002407 tissue scaffold Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000003656 tris buffered saline Substances 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
- 108010047303 von Willebrand Factor Proteins 0.000 description 1
- 102100036537 von Willebrand factor Human genes 0.000 description 1
- 229960001134 von willebrand factor Drugs 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000002759 woven fabric Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/00987—Apparatus or processes for manufacturing non-adhesive dressings or bandages
- A61F13/00991—Apparatus or processes for manufacturing non-adhesive dressings or bandages for treating webs, e.g. for moisturising, coating, impregnating or applying powder
- A61F13/00995—Apparatus or processes for manufacturing non-adhesive dressings or bandages for treating webs, e.g. for moisturising, coating, impregnating or applying powder for mechanical treatments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4833—Thrombin (3.4.21.5)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/363—Fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/26—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/28—Polysaccharides or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/38—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/64—Use of materials characterised by their function or physical properties specially adapted to be resorbable inside the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05D—PROCESSES FOR APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05D1/00—Processes for applying liquids or other fluent materials
- B05D1/02—Processes for applying liquids or other fluent materials performed by spraying
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05D—PROCESSES FOR APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05D1/00—Processes for applying liquids or other fluent materials
- B05D1/18—Processes for applying liquids or other fluent materials performed by dipping
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L71/00—Compositions of polyethers obtained by reactions forming an ether link in the main chain; Compositions of derivatives of such polymers
- C08L71/02—Polyalkylene oxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/418—Agents promoting blood coagulation, blood-clotting agents, embolising agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/04—Materials for stopping bleeding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Materials Engineering (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Organic Chemistry (AREA)
- Manufacturing & Machinery (AREA)
- Polymers & Plastics (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Materials For Medical Uses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161566051P | 2011-12-02 | 2011-12-02 | |
| US61/566,051 | 2011-12-02 | ||
| US13/324,115 | 2011-12-13 | ||
| US13/324,115 US9056092B2 (en) | 2011-12-02 | 2011-12-13 | Hemostatic bioabsorbable device with polyethylene glycol binder |
| PCT/US2012/066737 WO2013082073A1 (en) | 2011-12-02 | 2012-11-28 | Hemostatic bioabsorbable device with polyethylene glycol binder |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017100266A Division RU2646728C1 (ru) | 2011-12-02 | 2012-11-28 | Гемостатическое биологически абсорбируемое устройство с полиэтиленгликолем в качестве связующего вещества |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2014126807A RU2014126807A (ru) | 2016-02-10 |
| RU2627426C2 true RU2627426C2 (ru) | 2017-08-08 |
Family
ID=47279164
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014126807A RU2627426C2 (ru) | 2011-12-02 | 2012-11-28 | Гемостатическое биологически абсорбируемое устройство с полиэтиленгликолем в качестве связующего вещества |
| RU2017100266A RU2646728C1 (ru) | 2011-12-02 | 2012-11-28 | Гемостатическое биологически абсорбируемое устройство с полиэтиленгликолем в качестве связующего вещества |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017100266A RU2646728C1 (ru) | 2011-12-02 | 2012-11-28 | Гемостатическое биологически абсорбируемое устройство с полиэтиленгликолем в качестве связующего вещества |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US9056092B2 (enExample) |
| EP (1) | EP2785386B1 (enExample) |
| JP (1) | JP6147760B2 (enExample) |
| CN (1) | CN103957947B (enExample) |
| AU (2) | AU2012346104B2 (enExample) |
| BR (1) | BR112014013337B1 (enExample) |
| CA (1) | CA2857138A1 (enExample) |
| ES (1) | ES2659457T3 (enExample) |
| RU (2) | RU2627426C2 (enExample) |
| WO (1) | WO2013082073A1 (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10765774B2 (en) * | 2013-07-09 | 2020-09-08 | Ethicon, Inc. | Hemostatic pad assembly kit and method |
| US20180028725A1 (en) * | 2015-02-27 | 2018-02-01 | Polyganics Ip B.V. | Drug Eluting Foams and the Production Thereof |
| US10111661B2 (en) | 2015-08-31 | 2018-10-30 | Ethicon Llc | Matrix metalloproteinase inhibiting adjuncts for surgical devices |
| US10086116B2 (en) | 2015-08-31 | 2018-10-02 | Ethicon Llc | Adjunct material to provide controlled drug release |
| US10499913B2 (en) | 2015-08-31 | 2019-12-10 | Ethicon Llc | Tubular surgical constructs including adjunct material |
| US11020116B2 (en) | 2015-08-31 | 2021-06-01 | Ethicon Llc | Surgical adjuncts with medicants affected by activators |
| US9937283B2 (en) | 2015-08-31 | 2018-04-10 | Ethicon Endo-Surgery, Llc | Adjunct material to provide drug elution from vessels |
| US10172973B2 (en) | 2015-08-31 | 2019-01-08 | Ethicon Llc | Surgical adjuncts and medicants for promoting lung function |
| US10194936B2 (en) | 2015-08-31 | 2019-02-05 | Ethicon Endo-Surgery, Llc | Adjunct material for delivery to stomach tissue |
| US10188389B2 (en) | 2015-08-31 | 2019-01-29 | Ethicon Llc | Adjunct material for delivery to colon tissue |
| US10213520B2 (en) | 2015-08-31 | 2019-02-26 | Ethicon Llc | Surgical adjuncts having medicants controllably releasable therefrom |
| US10349938B2 (en) | 2015-08-31 | 2019-07-16 | Ethicon Llc | Surgical adjuncts with medicants affected by activator materials |
| US10285692B2 (en) | 2015-08-31 | 2019-05-14 | Ethicon Llc | Adjuncts for surgical devices including agonists and antagonists |
| US10076324B2 (en) | 2015-08-31 | 2018-09-18 | Ethicon Llc | Adjunct material to provide controlled drug elution |
| US10076329B2 (en) | 2015-08-31 | 2018-09-18 | Ethicon Llc | Adjunct material to promote tissue growth in a colon |
| US10188390B2 (en) | 2015-08-31 | 2019-01-29 | Ethicon Llc | Adjunct material to provide heterogeneous drug elution |
| US10245034B2 (en) | 2015-08-31 | 2019-04-02 | Ethicon Llc | Inducing tissue adhesions using surgical adjuncts and medicants |
| US10279086B2 (en) | 2015-08-31 | 2019-05-07 | Ethicon Llc | Composite adjunct materials for delivering medicants |
| US10463366B2 (en) | 2015-08-31 | 2019-11-05 | Ethicon Llc | Adjunct materials for delivery to liver tissue |
| US10130738B2 (en) | 2015-08-31 | 2018-11-20 | Ethicon Llc | Adjunct material to promote tissue growth |
| US10569071B2 (en) | 2015-08-31 | 2020-02-25 | Ethicon Llc | Medicant eluting adjuncts and methods of using medicant eluting adjuncts |
| NZ741447A (en) | 2015-11-06 | 2022-12-23 | Ethicon Inc | Compacted hemostatic cellulosic aggregates |
| CN107754005B (zh) * | 2016-08-15 | 2021-06-15 | 广州倍绣生物技术有限公司 | 止血组合物及其制造方法 |
| US11413335B2 (en) * | 2018-02-13 | 2022-08-16 | Guangzhou Bioseal Biotech Co. Ltd | Hemostatic compositions and methods of making thereof |
| US11254061B2 (en) | 2017-01-06 | 2022-02-22 | Ethicon, Inc. | Scaffolds for implanting absorbable hemostats in field conditions |
| CN108498879B (zh) | 2017-02-28 | 2021-12-28 | 苏州安德佳生物科技有限公司 | 黏膜下注射用组合物和试剂组合及其应用 |
| BR112019018010A2 (pt) * | 2017-03-09 | 2020-04-28 | Baxter Healthcare Sa | sistema e métodos de deposição de solventes |
| JP6868129B2 (ja) * | 2017-10-13 | 2021-05-12 | グンゼ株式会社 | 生体組織補強材料キット及び生体組織補強材料 |
| CN110025821A (zh) | 2018-01-12 | 2019-07-19 | 北京环球利康科技有限公司 | 使用生物相容性止血剂和组织封闭剂的组合物处理活动性出血的方法 |
| CN113166246B (zh) | 2018-12-28 | 2024-10-18 | 四川科伦博泰生物医药股份有限公司 | 一种抗体及其用途 |
| US11241386B2 (en) * | 2019-02-13 | 2022-02-08 | Biolife, L.L.C. | Wound sealing powder |
| EP4069324B1 (en) * | 2019-12-06 | 2025-05-21 | Guangzhou Bioseal Biotech Co., Ltd. | Flowable fibrinogen thrombin paste |
| JP7397646B2 (ja) * | 2019-12-12 | 2023-12-13 | グンゼ株式会社 | 自動縫合器用縫合補強材 |
| US12070522B2 (en) | 2020-02-18 | 2024-08-27 | Ethicon, Inc. | Melt blown dressing with gradient density |
| IL298184A (en) * | 2020-05-15 | 2023-01-01 | Sichuan Kelun Biotech Biopharmaceutical Co Ltd | Antibody drug conjugate, preparation method therefor and use thereof |
| US11826028B2 (en) * | 2020-06-10 | 2023-11-28 | Ethicon, Inc. | Two component sealing systems including synthetic matrices and biosynthetic adhesives for sealing resected surfaces of organs to control bleeding, fluid leaks and air leaks |
| CN113599568A (zh) * | 2021-08-05 | 2021-11-05 | 南方科技大学 | 合成材料类粉剂及其在止血体系的应用 |
| WO2023119265A1 (en) | 2021-12-21 | 2023-06-29 | Omrix Biopharmaceuticals Ltd. | Fibrinogen comprising formulation and uses thereof |
| CN114272432B (zh) * | 2021-12-22 | 2023-03-17 | 山东百多安医疗器械股份有限公司 | 一种可用于脑外科的新型止血海绵复合材料的制备方法 |
| CN116509629B (zh) * | 2023-05-29 | 2025-12-05 | 青岛富瑞沃新材料有限公司 | 一种水胶体敷料及其制造方法 |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4427650A (en) * | 1981-06-25 | 1984-01-24 | Serapharm Michael Stroetmann | Enriched plasma derivative for advancement of wound closure and healing |
| RU2238047C1 (ru) * | 2003-04-22 | 2004-10-20 | Санкт-Петербургская медицинская академия последипломного образования | Способ лечения раны после удаления зуба или имплантата |
| US20060088589A1 (en) * | 2004-10-20 | 2006-04-27 | Gorman Anne J | Reinforced absorbable multilayered hemostatic wound dressing |
| US20090246238A1 (en) * | 2004-10-20 | 2009-10-01 | Anne Jessica Gorman | Reinforced absorbable multilayered hemostatic wound dressing |
| US20110071499A1 (en) * | 2009-09-18 | 2011-03-24 | Dorna Hakimimehr | Free-standing biodegradable patch |
| US20110171282A1 (en) * | 2007-06-19 | 2011-07-14 | Rynel Inc. | Materials Comprising Water-Soluble Polymer Particles and Methods of Making and Using Them |
| US20110275972A1 (en) * | 2008-10-02 | 2011-11-10 | L.R.R.& D. Ltd. | Interface layer wound dressing |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5308896A (en) * | 1992-08-17 | 1994-05-03 | Weyerhaeuser Company | Particle binders for high bulk fibers |
| CA2245585A1 (en) | 1996-02-06 | 1997-08-14 | David P. Kosow | Composition for sealing wounds |
| US7320962B2 (en) | 1996-08-27 | 2008-01-22 | Baxter International Inc. | Hemoactive compositions and methods for their manufacture and use |
| US6706690B2 (en) | 1999-06-10 | 2004-03-16 | Baxter Healthcare Corporation | Hemoactive compositions and methods for their manufacture and use |
| US6056970A (en) * | 1998-05-07 | 2000-05-02 | Genzyme Corporation | Compositions comprising hemostatic compounds and bioabsorbable polymers |
| FR2783429B1 (fr) * | 1998-09-18 | 2002-04-12 | Imedex Biomateriaux | Materiau collagenique bicomposite,son procede d'obtention et ses applications therapeutiques |
| AU754458B2 (en) * | 1998-12-23 | 2002-11-14 | Csl Behring Gmbh | Fibrin-based glue granulate and corresponding production method |
| US7572769B2 (en) * | 1998-12-23 | 2009-08-11 | Csl Behring Gmbh | Fibrin adhesive granulate and method for its preparation |
| AU2005295367B2 (en) | 2004-10-20 | 2010-12-02 | Ethicon, Inc. | A reinforced absorbable multilayered fabric for use in medical devices and method of manufacture |
| CN101084022A (zh) * | 2004-10-20 | 2007-12-05 | 伊西康公司 | 可吸收的止血物 |
| US8277837B2 (en) | 2006-01-11 | 2012-10-02 | Entegrion, Inc. | Hemostatic textile |
| BRPI0718145B8 (pt) * | 2006-11-02 | 2021-05-25 | Omrix Biopharmaceuticals Ltd | método de micronização |
| US20090053288A1 (en) | 2007-08-20 | 2009-02-26 | Eskridge Jr E Stan | Hemostatic woven fabric |
| CN102218155A (zh) * | 2010-04-16 | 2011-10-19 | 浙江医鼎医用敷料有限公司 | 纳米银功能性水胶体医用敷料的制备方法 |
-
2011
- 2011-12-13 US US13/324,115 patent/US9056092B2/en active Active
-
2012
- 2012-11-28 CA CA2857138A patent/CA2857138A1/en not_active Abandoned
- 2012-11-28 JP JP2014544830A patent/JP6147760B2/ja not_active Expired - Fee Related
- 2012-11-28 RU RU2014126807A patent/RU2627426C2/ru not_active IP Right Cessation
- 2012-11-28 WO PCT/US2012/066737 patent/WO2013082073A1/en not_active Ceased
- 2012-11-28 AU AU2012346104A patent/AU2012346104B2/en not_active Ceased
- 2012-11-28 BR BR112014013337-9A patent/BR112014013337B1/pt not_active IP Right Cessation
- 2012-11-28 EP EP12795313.1A patent/EP2785386B1/en not_active Not-in-force
- 2012-11-28 ES ES12795313.1T patent/ES2659457T3/es active Active
- 2012-11-28 CN CN201280058779.1A patent/CN103957947B/zh not_active Expired - Fee Related
- 2012-11-28 RU RU2017100266A patent/RU2646728C1/ru not_active IP Right Cessation
-
2015
- 2015-05-08 US US14/707,559 patent/US9351883B2/en active Active
- 2015-10-27 AU AU2015249039A patent/AU2015249039B2/en not_active Ceased
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4427650A (en) * | 1981-06-25 | 1984-01-24 | Serapharm Michael Stroetmann | Enriched plasma derivative for advancement of wound closure and healing |
| RU2238047C1 (ru) * | 2003-04-22 | 2004-10-20 | Санкт-Петербургская медицинская академия последипломного образования | Способ лечения раны после удаления зуба или имплантата |
| US20060088589A1 (en) * | 2004-10-20 | 2006-04-27 | Gorman Anne J | Reinforced absorbable multilayered hemostatic wound dressing |
| US20090246238A1 (en) * | 2004-10-20 | 2009-10-01 | Anne Jessica Gorman | Reinforced absorbable multilayered hemostatic wound dressing |
| US20110171282A1 (en) * | 2007-06-19 | 2011-07-14 | Rynel Inc. | Materials Comprising Water-Soluble Polymer Particles and Methods of Making and Using Them |
| US20110275972A1 (en) * | 2008-10-02 | 2011-11-10 | L.R.R.& D. Ltd. | Interface layer wound dressing |
| US20110071499A1 (en) * | 2009-09-18 | 2011-03-24 | Dorna Hakimimehr | Free-standing biodegradable patch |
Non-Patent Citations (1)
| Title |
|---|
| В.И. ЧУЕШОВ. Промышленная технология лекарств. Том 1. Харьков, издательство НФАУ, 2002, стр. 24, 1,2 абзацы. * |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2015249039B2 (en) | 2016-06-23 |
| ES2659457T3 (es) | 2018-03-15 |
| CN103957947B (zh) | 2018-09-07 |
| CA2857138A1 (en) | 2013-06-06 |
| CN103957947A (zh) | 2014-07-30 |
| US9351883B2 (en) | 2016-05-31 |
| AU2012346104A1 (en) | 2014-05-29 |
| AU2012346104B2 (en) | 2015-11-12 |
| BR112014013337A2 (pt) | 2017-06-13 |
| JP2015500059A (ja) | 2015-01-05 |
| US9056092B2 (en) | 2015-06-16 |
| BR112014013337B1 (pt) | 2019-10-15 |
| AU2015249039A1 (en) | 2015-11-12 |
| EP2785386B1 (en) | 2018-01-17 |
| US20130149343A1 (en) | 2013-06-13 |
| RU2646728C1 (ru) | 2018-03-06 |
| RU2014126807A (ru) | 2016-02-10 |
| EP2785386A1 (en) | 2014-10-08 |
| JP6147760B2 (ja) | 2017-06-14 |
| WO2013082073A1 (en) | 2013-06-06 |
| US20150238366A1 (en) | 2015-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2646728C1 (ru) | Гемостатическое биологически абсорбируемое устройство с полиэтиленгликолем в качестве связующего вещества | |
| JP6363186B2 (ja) | 止血パッドのアセンブリキット及び方法 | |
| KR101387372B1 (ko) | 지혈용 직물 | |
| EP1718147B1 (en) | Hemostatic agent for topical and internal use | |
| CA2529717C (en) | Deployable hemostatic agent | |
| RU2756891C2 (ru) | Гемостатические композиции и способы их получения | |
| BR112012029190B1 (pt) | Pano em múltiplas camadas absorvível e reforçado para aplicações hemostáticas | |
| BR112012029293B1 (pt) | Pano hemostático sintético e seu método de fabricação | |
| AU3788299A (en) | Compositions comprising hemostatic compounds and bioabsorbable polymers | |
| US11484623B2 (en) | Dry pad comprising thrombin and pectin | |
| US20220023491A1 (en) | Hemostatic Composite Aggregate Materials Having Surface Enriched with Hemostatis | |
| HK1124268A (zh) | 可展开的止血剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20201129 |